300 related articles for article (PubMed ID: 16000365)
1. Osteonecrosis of the jaw and bisphosphonates.
Durie BG; Katz M; Crowley J
N Engl J Med; 2005 Jul; 353(1):99-102; discussion 99-102. PubMed ID: 16000365
[No Abstract] [Full Text] [Related]
2. Osteonecrosis of the jaw and bisphosphonates.
Maerevoet M; Martin C; Duck L
N Engl J Med; 2005 Jul; 353(1):99-102; discussion 99-102. PubMed ID: 16003838
[No Abstract] [Full Text] [Related]
3. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
Kraj M; Pogłód R; Maj S; Owczarska K
Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
[No Abstract] [Full Text] [Related]
4. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the jaw and bisphosphonates.
Woo SB; Hande K; Richardson PG
N Engl J Med; 2005 Jul; 353(1):99-102; discussion 99-102. PubMed ID: 16003837
[No Abstract] [Full Text] [Related]
6. [Rapid drug information].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):506-7. PubMed ID: 15830265
[No Abstract] [Full Text] [Related]
7. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates and osteonecrosis of the jaw.
Shenker NG; Jawad AS
Rheumatology (Oxford); 2007 Jul; 46(7):1049-51. PubMed ID: 17500074
[No Abstract] [Full Text] [Related]
9. Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration.
Oteri G; Allegra A; Bellomo G; Alonci A; Nastro E; Penna G; Catalfamo L; Cicciù D; De Ponte FS; Musolino C
Cytokine; 2008 Aug; 43(2):103-4. PubMed ID: 18585926
[No Abstract] [Full Text] [Related]
10. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
Delibasi T; Altundag K; Kanlioglu Y
J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
[No Abstract] [Full Text] [Related]
11. Multiple myeloma.
Altundag K; Altundag O; Gundeslioglu O
N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15728824
[No Abstract] [Full Text] [Related]
12. Jaw complications in breast and prostate cancer patients treated with zoledronic acid.
Ortega C; Faggiuolo R; Vormola R; Montemurro F; Nanni D; Goia F; Aglietta M
Acta Oncol; 2006; 45(2):216-7. PubMed ID: 16546871
[No Abstract] [Full Text] [Related]
13. Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
Pastor-Zuazaga D; Garatea-Crelgo J; Martino-Gorbea R; Etayo-Pérez A; Sebastián-López C
Med Oral Patol Oral Cir Bucal; 2006 Jan; 11(1):E76-9. PubMed ID: 16388300
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates--role in cancer therapies.
Mehrotra B
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
[No Abstract] [Full Text] [Related]
15. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
Ruggiero SL; Fantasia J; Carlson E
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):433-41. PubMed ID: 16997108
[No Abstract] [Full Text] [Related]
16. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
[TBL] [Abstract][Full Text] [Related]
17. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.
Bagan JV; Jimenez Y; Murillo J; Hernandez S; Poveda R; Sanchis JM; Diaz JM; Scully C
Oral Oncol; 2006 Mar; 42(3):327-9. PubMed ID: 16275156
[No Abstract] [Full Text] [Related]
18. [The complications during the therapy for multiple myeloma].
Spicka I
Vnitr Lek; 2006 Feb; 52(2):115. PubMed ID: 16623271
[No Abstract] [Full Text] [Related]
19. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Marx RE; Sawatari Y; Fortin M; Broumand V
J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.
Jimenez-Soriano Y; Bagan JV
Med Oral Patol Oral Cir Bucal; 2005 Jul; 10 Suppl 2():E88-91. PubMed ID: 15995577
[No Abstract] [Full Text] [Related]
[Next] [New Search]
